Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell | PTCE Pharmacy Connect

Educational Objective: Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma. Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist - Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Plantation, Florida Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023. This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.